The BMT CTN offers a range of multi-institutional Phase II and III clinical trial protocols focused directly on improving patient outcomes and advancing the science of cellular therapy. The Network has answered important questions in both common and rare diseases. Our research portfolio includes studies in leukemia, myelodysplasia, lymphoma, and multiple myeloma as well as rare transplant indications, such as aplastic anemia, sickle cell disease, human immunodeficiency virus (HIV)-associated cancers, and hemophagocytic syndromes / primary immune deficiencies. Network trials address critical issues in optimal graft sources, conditioning intensity, regimen-related toxicity, engraftment, graft-versus-host disease (GVHD), infection, disease control, and quality of life. Learn more about these protocols through the links below or visit the BMT CTN website to get the most recent protocol list.